Recently, a randomized phase III study (NEJ009) showed that compared with gefitinib alone, gefitinib combined with carboplatin plus pemetrexed improved PFS in patients with untreated advanced NSCLC with EGFR mutations (20.9 vs 11.2 months, P < 0.001) (9). This evidence concerns the gene EGFR and non-small cell lung carcinoma.